اكتشف أفضل عيادات وتكاليف العلاج فقر الدم الانحلالي في إسرائيل 2026

Tel Aviv Sourasky Medical Center and Sheba Medical Center are top-equipped Israeli hospitals for treating hemolytic anemia. These JCI-accredited tertiary centers provide specialized hematology units. They offer advanced immune-suppressing therapies and plasmapheresis. Both facilities maintain robust blood banks to manage severe crises safely.

• Specialized diagnostics: Advanced Doppler imaging and blood panels identify complex red blood cell destruction.
• Expert leadership: Dr. Abraham Avigdor at Sheba Medical Center leads precision blood disorder diagnostics.
• Pediatric expertise: Dr. Hana Golan manages chronic and inherited blood disorders in children.
• Regional referrals: Rambam Health Care Campus serves as the primary hub for northern Israel.

Bookimed Expert Insight: Israeli hematology departments offer high-level expertise, but patient volume varies. Sourasky Medical Center treats over 1,800,000 patients annually across its departments. This high volume often results in more streamlined protocols for rare autoimmune cases. When choosing a specialist, look for leaders like Prof. Avichai Shimoni. His diverse background in pediatrics and adult hematology is vital for transition care.

Patient Consensus: Patients note it is important to find centers with active immunotherapy protocols. Many emphasize choosing doctors experienced with rituximab rather than rushing into a splenectomy.

Israeli hematologists identify hemolytic anemia types using a structured combination of laboratorial, morphological, and molecular techniques. Specialists employ direct antiglobulin testing (DAT) and flow cytometry to differentiate immune-mediated causes. Advanced centers use hemoglobin electrophoresis and next-generation sequencing for definitive hereditary diagnosis within JCI-accredited facilities.

• Primary screening: Lab panels establish active hemolysis via haptoglobin levels and reticulocyte counts.
• Immune typing: Direct antiglobulin test (Coombs test) identifies antibodies targeting red blood cells.
• Morphological analysis: Peripheral blood smears visualize spherocytes or schistocytes to pinpoint specific etiologies.
• Genetic mapping: Targeted next-generation sequencing (NGS) panels isolate rare mutations in inherited variants.

Bookimed Expert Insight: Israeli hematology centers often use flow cytometry and PET/CT imaging as integrated prognostic tools for complex blood disorders. For example, Dr. Abraham Avigdor at Sheba Medical Center uses PET/CT to monitor treatment response. This allows doctors to adjust therapies faster than standard blood work alone might suggest. Choosing a center with these combined capabilities ensures more precise long-term management.

Patient Consensus: Patients note that standard tests can miss rare variants. They recommend requesting genetic panels for genes like PKLR or SPTA1 early in the process. Many patients find that centers with advanced flow cytometry expertise provide much faster results for specific typing.

Advanced hemolytic anemia protocols in Israel integrate monoclonal antibodies and cellular therapies within JCI-accredited facilities. Specialized hematology units employ rituximab and complement inhibitors to target autoimmune destruction. Curative options include allogeneic stem cell transplantation. Automated plasma exchange provides urgent stabilization for refractory cases.

• Targeted biologicals: Rituximab depletes autoreactive B-cells in steroid-resistant cases.
• Complement inhibitors: Eculizumab or sutimlimab directly halt intravascular hemolysis.
• Cellular therapy: Leading centers offer autologous and allogeneic stem cell transplants.
• Stabilization protocols: High-volume plasmapheresis removes harmful IgM antibodies during crises.

Bookimed Expert Insight: Israeli hematology leadership is defined by academic depth. Both Dr. Abraham Avigdor and Dr. Avichai Shimoni at Sheba Medical Center possess over 30+ years of experience. This expertise is a byproduct of high patient volumes. Sourasky Medical Center treats over 400,000 patients every year. These physicians don't just follow protocols. They actively author them. Dr. Avigdor has published 130+ scientific works. Dr. Shimoni has authored over 250+. For patients, this means access to research-grade diagnostics like PET/CT and experimental trials often before they reach other regions.

Patient Consensus: Patients emphasize the importance of early genetic testing to identify specific sub-types before starting steroid treatment. Many note that combining rituximab with intravenous immunoglobulin (IVIG) serves as an effective bridge therapy while waiting for long-term remission.

International patients can access clinical trials for refractory Autoimmune Hemolytic Anemia (AIHA). Eligibility depends on trial design and country-specific laws. Israeli centers often participate in global multicenter trials. Participation requires meeting strict inclusion criteria. Documented failure of standard therapies is necessary.

• Global enrollment: Many phase 3 trials are multi-country initiatives.
• Refractory status: Trials require documented failure of corticosteroids or rituximab.
• Diagnostic criteria: Research often targets warm AIHA or Cold Agglutinin Disease.
• Physician sponsorship: International applicants usually need a local Israeli doctor sponsor.

Bookimed Expert Insight: Israeli specialists like Dr. Hana Golan and Dr. Amos Toren serve as primary investigators for international trials. Data shows these academic headers bridge trials with compassionate use programs. If trial criteria exclude you, these experts often facilitate off-label access to newer drugs like fostamatinib.

Patient Consensus: Patients note that traveling for trials requires significant self-funding and private medical referrals. Many prioritize seeking compassionate use access to advanced therapies when formal trial residency requirements are too strict.